{"id":38887,"date":"2026-06-30T09:51:00","date_gmt":"2026-06-30T13:51:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38887"},"modified":"2026-05-12T09:02:19","modified_gmt":"2026-05-12T13:02:19","slug":"four-secondary-patent-types-that-extend-drug-exclusivity-beyond-the-primary-patent","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/four-secondary-patent-types-that-extend-drug-exclusivity-beyond-the-primary-patent\/","title":{"rendered":"Four Secondary Patent Types That Extend Drug Exclusivity Beyond the Primary Patent"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The primary compound patent on a drug is the one the industry talks about. It sets the nominal expiry date that Wall Street marks in its models, the one that generic manufacturers circle on their calendars years in advance. But the compound patent is rarely the last line of defense. In most blockbuster franchises, the real work of protecting revenue happens in the second ring of the IP structure, where formulation patents, method-of-use patents, metabolite patents, and polymorph patents operate as a coordinated defense layer that can push effective market exclusivity years past the primary expiry.<\/p>\n\n\n\n

This article takes apart that secondary architecture piece by piece. Each patent type has different legal mechanics, different vulnerability to challenge, and a different commercial payoff profile. Understanding them separately, and how they interact, is the starting point for any serious analysis of a drug’s loss-of-exclusivity (LOE) risk.<\/p>\n\n\n\n

The practical stakes are not abstract. Bristol-Myers Squibb’s Eliquis (apixaban) carried compound patent protection through roughly 2026, but a web of formulation and method-of-use patents pushed anticipated generic entry dates into the late 2020s subject to ongoing litigation outcomes. AstraZeneca extended Nexium (esomeprazole) via polymorph and formulation patents long after the omeprazole base patent family lapsed. AbbVie’s patent thicket around Humira (adalimumab) held biosimilars off the U.S. market until 2023 despite the core biologic patents expiring years earlier. The mechanisms differ across small molecules and biologics, but the logic is identical: secondary patents fill the gap between nominal compound expiry and the date when competition actually arrives.<\/p>\n\n\n\n

Data tracking these secondary patent portfolios has become an industry in itself. Tools like DrugPatentWatch<\/a> aggregate Orange Book listings, patent term extension records, Paragraph IV certification histories, and inter partes review (IPR) outcomes to give analysts a structured view of a drug’s full IP runway, not just its primary expiry headline.<\/p>\n\n\n\n

What follows is an analysis of each of the four secondary patent types, grounded in real cases, real court outcomes, and the commercial mechanics that determine how much exclusivity each one actually delivers.<\/p>\n\n\n\n

\n\n\n\n

The Architecture of Drug Patent Protection: Primary vs. Secondary Patents<\/strong><\/h2>\n\n\n\n

What Is a Primary Compound Patent and Why It Is Never Enough<\/strong><\/h3>\n\n\n\n

A compound patent, also called a composition-of-matter patent, covers the active pharmaceutical ingredient (API) itself. It is the broadest, most defensible patent a drug company can hold because it blocks any use of that molecule in any form for any indication. When it expires, the core IP gate opens. Generic manufacturers no longer need a license to make and sell the API.<\/p>\n\n\n\n

The problem for originators is timing. The average time from filing a compound patent to receiving FDA approval for the corresponding drug is roughly 12 years, and often longer. Since patent terms run 20 years from filing date, a drug may enter the market with only 8 to 10 years of compound patent life remaining. After subtracting time spent on FDA review, a five-year patent term extension under 35 U.S.C. \u00a7 156 can recover some of that time, but the statutory cap on the total remaining term after extension is 14 years from FDA approval. For many drugs, that still leaves a meaningful revenue gap between when they want to maximize returns and when the compound patent actually expires.<\/p>\n\n\n\n

Secondary patents address that gap. They are filed later in the drug’s development lifecycle, often during or after clinical trials, and they cover aspects of the drug other than the basic molecule. Because they are filed later, their 20-year terms run later. A formulation patent filed two years before NDA approval may expire six or eight years after the compound patent. A method-of-use patent covering a new indication approved post-launch can run even longer.<\/p>\n\n\n\n

How the Orange Book Formalizes Secondary Patent Listings<\/strong><\/h3>\n\n\n\n

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, universally known as the Orange Book, is the legal scaffold for secondary patent protection in the United States. Any patent an NDA holder believes could be infringed by a generic’s ANDA must be listed there. An ANDA filer must then certify to each listed patent, and a Paragraph IV certification, which asserts that the patent is invalid or will not be infringed, triggers a 30-month stay of FDA approval and a potential 180-day generic exclusivity period for the first filer.<\/p>\n\n\n\n

Secondary patents earn their place in the Orange Book because they qualify under the listing rules for product patents (covering the drug substance or drug product) and method-of-use patents (covering an approved use). Polymorph patents, formulation patents, and metabolite patents can all qualify as product patents. Method-of-use patents qualify if they cover an approved indication.<\/p>\n\n\n\n

The listing rules also create a practical enforcement mechanism. Once a patent is in the Orange Book, every ANDA filer must address it. That means litigation costs and 30-month stays multiply with each new patent listed. A product with four secondary patents listed in the Orange Book potentially generates four separate 30-month litigation windows, though courts have scrutinized stays where the patents are clearly distinct from the challenged product.<\/p>\n\n\n\n

Secondary Patent Strategy vs. Patent Evergreening: Where the Line Falls<\/strong><\/h3>\n\n\n\n

Critics call secondary patent portfolios ‘evergreening,’ a term that implies illegitimate extension of monopoly power through trivial or obvious modifications. The pharmaceutical industry pushes back hard on that framing, arguing that post-approval innovations in formulation or delivery represent real R&D investment with genuine patient benefit.<\/p>\n\n\n\n

Both positions contain truth. Some secondary patents cover genuinely non-obvious innovations. Once-daily extended-release formulations of drugs previously dosed three times daily represent pharmacokinetic advances that improve adherence and reduce side effects. A method-of-use patent covering a newly discovered oncology indication for an existing cardiovascular drug reflects years of clinical work. These are not trivial.<\/p>\n\n\n\n

Other secondary patents test the edges of patentability. A patent on a crystalline form of a compound that displays no meaningfully different clinical properties compared to the amorphous form is the kind of filing that draws regulatory and legislative scrutiny. The India Patent Office famously denied Novartis patent protection for the beta-crystalline form of imatinib (Gleevec\/Glivec) under Section 3(d) of the Indian Patents Act, which requires enhanced efficacy to patent a new form of an existing compound. U.S. law does not have a direct analog, but the obviousness standard under 35 U.S.C. \u00a7 103 provides some check on patents that offer no real innovation beyond the primary compound.<\/p>\n\n\n\n

For commercial analysis, the normative debate matters less than the practical question: how often do secondary patents hold up in litigation, and how much exclusivity do they actually deliver? That question has different answers for each patent type.<\/p>\n\n\n\n

\n\n\n\n

Formulation Patents: The Most Commercially Reliable Secondary Protection<\/strong><\/h2>\n\n\n\n

What Formulation Patents Cover and How They Are Structured<\/strong><\/h3>\n\n\n\n

A formulation patent covers the specific pharmaceutical composition of a drug product: the combination of the API with excipients, stabilizers, delivery systems, coatings, or controlled-release mechanisms. It does not protect the molecule itself, but it protects the way that molecule is packaged for therapeutic use.<\/p>\n\n\n\n

Formulation patents come in several varieties. Immediate-release formulation patents cover the specific excipient blend and manufacturing process used in standard tablets or capsules. Extended-release patents protect the polymer matrices, osmotic systems, or multi-layer tablet architectures that control drug release rates. Parenteral formulation patents cover injectable or infusible products where the formulation work is complex: lyophilization processes, pH adjustment, solubilizing agents, and stability solutions. Transdermal and inhaled formulation patents protect patch designs, propellant systems, and particle size specifications in inhalers.<\/p>\n\n\n\n

The scope of protection in a formulation patent is shaped by the specificity of its claims. Broad claims covering any controlled-release formulation of a compound are harder to obtain, because prior art for controlled-release technology is extensive. Narrow claims tied to specific excipient ratios or polymer types are easier to defend as novel and non-obvious, but a generic developer can design around them more easily. The prosecution history, meaning what was argued and conceded during patent examination, determines the doctrine of equivalents scope and how far claims can be stretched in litigation.<\/p>\n\n\n\n

Extended-Release Formulation Patents: Case Study in Oxycodone, Metoprolol, and Venlafaxine<\/strong><\/h3>\n\n\n\n

Purdue Pharma’s extended-release oxycodone product, OxyContin, illustrates both the commercial power and the legal vulnerability of formulation patents. The original compound, oxycodone hydrochloride, had no IP protection. OxyContin’s competitive position depended entirely on its controlled-release formulation patents. When Endo Pharmaceuticals and other generic manufacturers challenged those patents via Paragraph IV filings in the early 2000s, Purdue ultimately settled, granting authorized generics and accepting a 2004 generic entry date that wiped out the original commercial model. The formulation patents provided years of exclusivity, but not indefinite protection.<\/p>\n\n\n\n

AstraZeneca’s experience with Toprol-XL (metoprolol succinate extended release) follows a different arc. AstraZeneca held formulation patents that generic manufacturers challenged aggressively. The litigation settled, but the generic entry timeline stretched into the mid-2000s, generating billions in protected revenue after the underlying compound patent on metoprolol had long since expired. The formulation, not the molecule, was the commercial asset.<\/p>\n\n\n\n

Wyeth (now part of Pfizer) extended Effexor XR (venlafaxine hydrochloride extended release) through similar formulation patent coverage. The immediate-release formulation faced generic competition years before the XR franchise came under serious threat. When Teva and other ANDA filers challenged the XR formulation patents, the litigation produced mixed outcomes. Some claims held, some were invalidated on obviousness grounds, and the effective generic entry date fell somewhere in the middle of what Wyeth had hoped to defend.<\/p>\n\n\n\n

How Generic Manufacturers Argue Around Formulation Patents in ANDA Litigation<\/strong><\/h3>\n\n\n\n

Generic manufacturers attacking formulation patents in Paragraph IV litigation focus on two statutory invalidity arguments: obviousness under 35 U.S.C. \u00a7 103 and anticipation under 35 U.S.C. \u00a7 102. The obviousness argument is usually stronger for formulation patents than for compound patents, because the prior art base for controlled-release and formulation technology is extensive. Scientific publications, prior patents on polymer matrices, and regulatory filings for other drugs often provide more than sufficient prior art to argue that combining a known API with known excipient technology was routine to a person of ordinary skill.<\/p>\n\n\n\n

A second angle is non-infringement. A generic formulation using different excipients or a different release mechanism may not fall within the patent claims even if the clinical result is similar. This is the design-around strategy. If the Orange Book-listed patent claims specifically require, for instance, a hydroxypropyl methylcellulose polymer at 15% to 25% concentration, a generic using a different polymer entirely avoids infringement regardless of whether the clinical bioequivalence is identical.<\/p>\n\n\n\n

Courts have seen both approaches succeed and fail. The Federal Circuit has consistently applied a fact-intensive analysis for formulation patent obviousness that is difficult to predict in advance. The pharmaceutical industry’s rate of formulation patent survival in Paragraph IV litigation is significantly lower than for compound patents, largely because the technical distinctions between novel and obvious are finer in formulation science than in synthetic chemistry.<\/p>\n\n\n\n

Formulation Patent Term and Orange Book Listing Timelines<\/strong><\/h3>\n\n\n\n

The commercial value of a formulation patent depends critically on when it was filed relative to the drug’s launch date and the compound patent’s expiry. A formulation patent filed during early clinical trials and listing a priority date of, say, 2005 for a drug approved in 2010 runs through 2025 at base term. With a potential five-year patent term extension under \u00a7 156 for the portion of regulatory review that counts toward extension, the term could reach 2028 or 2030.<\/p>\n\n\n\n

If the compound patent on that same drug expires in 2024, the formulation patent provides four to six years of additional exclusivity. At a $3 billion annual revenue run rate, that is $12 to $18 billion in protected sales. These are the numbers that justify the legal costs of defending the formulation portfolio.<\/p>\n\n\n\n

The Orange Book listing rules require that formulation patents be listed within 30 days of issue for already-approved drugs. Originators monitor continuation patent applications specifically to time issuance close to anticipated ANDA filings from generics. A patent issuing six months before the first Paragraph IV notice provides 30 months of stay from that date, potentially covering a full patent expiry runway.<\/p>\n\n\n\n

\n\n\n\n

Method-of-Use Patents: When Indications Become the Moat<\/strong><\/h2>\n\n\n\n

What Method-of-Use Patents Cover Under 35 U.S.C. \u00a7 101 and \u00a7 271(b)<\/strong><\/h3>\n\n\n\n

A method-of-use patent covers a specific way of using a pharmaceutical compound: treating a particular disease, dosing at a specific interval, administering to a specific patient population, or combining the compound with another therapy. Unlike formulation patents, method-of-use patents do not require any change to the drug product itself. The same tablet, same dose, same manufacturing process can be covered by a method-of-use patent if the indication or treatment protocol is novel and non-obvious.<\/p>\n\n\n\n

For Orange Book listing purposes, a method-of-use patent qualifies if it covers a use for which FDA approval was sought or obtained. This has important implications: a method-of-use patent covering an indication that has not been approved cannot be listed in the Orange Book and cannot trigger a 30-month stay. It also means that if a generic’s approved label carves out the patented use, a so-called skinny label under \u00a7 505(j)(2)(A)(viii), the patent infringement claim becomes substantially harder to sustain.<\/p>\n\n\n\n

Induced infringement under 35 U.S.C. \u00a7 271(b) is the central theory in method-of-use patent litigation where skinny labels are involved. If a generic’s label instructs physicians to prescribe the drug for the patented use, or if the generic manufacturer knows that its product will overwhelmingly be used for that purpose, induced infringement can be established even without the patented use on the label. The Supreme Court’s ruling in Global-Tech Appliances v. SEB S.A. set the knowledge standard for induced infringement: the defendant must have actually known, or been willfully blind to the fact, that it was inducing infringement.<\/p>\n\n\n\n

The Skinny Label Defense: What It Is, How It Works, and When It Fails<\/strong><\/h3>\n\n\n\n

When a generic drug has multiple approved indications and one or more of those indications is covered by an Orange Book-listed method-of-use patent, the ANDA filer can seek approval for only the non-patented indications. The resulting drug product with a label that omits the patented indication is the skinny label product.<\/p>\n\n\n\n

The skinny label defense has a long track record but an increasingly complicated legal history. For years, it provided a reliable design-around mechanism for method-of-use patents. If an originator held a method-of-use patent only for, say, reducing cardiovascular risk in patients with established cardiovascular disease, a generic could carve out that indication from its label and market the drug for other approved uses.<\/p>\n\n\n\n

The Federal Circuit’s 2021 decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA disrupted that reliability. The case involved Coreg (carvedilol), where GSK held a method-of-use patent covering treatment of congestive heart failure. Teva’s skinny label excluded the heart failure indication but retained other cardiovascular uses. Despite the carve-out, GSK argued that Teva’s promotional activities effectively induced physicians to prescribe the drug for the patented use. The Federal Circuit, in a 2-1 decision, found sufficient evidence of induced infringement partly based on Teva’s press releases and marketing that described carvedilol as used in heart failure patients.<\/p>\n\n\n\n

The decision sent a wave of concern through the generic industry. If press releases referencing a drug’s established clinical history can generate induced infringement liability despite a skinny label, the design-around value of the skinny label mechanism is compromised. The dissent in the Teva case argued that the majority had created an unworkable standard that would effectively extend method-of-use patent protection beyond its intended scope.<\/p>\n\n\n\n

GSK’s Lamivudine and the Multi-Indication Patent Strategy<\/strong><\/h3>\n\n\n\n

ViiV Healthcare (originally GSK) built a method-of-use portfolio around lamivudine (3TC) that illustrates the multi-indication patent strategy in HIV therapy. The compound itself had long-lapsed patent protection, but method-of-use patents covering specific treatment regimens, combination therapies, and dosing protocols in HIV management allowed ViiV to maintain commercial relevance for the molecule in branded combinations.<\/p>\n\n\n\n

The key tactic is sequencing. A drug approved first for HIV is later studied in hepatitis B. Method-of-use patents on the hepatitis B indication are filed and listed in the Orange Book separately from the original HIV patents. A generic seeking approval for the HIV use faces the original compound and formulation patents. A generic seeking approval for hepatitis B use faces the later-filed method-of-use patents with later expiry dates.<\/p>\n\n\n\n

Method-of-Use Patents in Oncology: Nivolumab, Pembrolizumab, and the Indication Expansion Model<\/strong><\/h3>\n\n\n\n

Oncology has become the most aggressive arena for method-of-use patent strategy. Immune checkpoint inhibitors approved for a single tumor type at launch are quickly studied across dozens of indication expansions. Each new approval creates a potential Orange Book listable method-of-use patent with a fresh prosecution history and a distinct expiry date.<\/p>\n\n\n\n

Bristol-Myers Squibb’s nivolumab (Opdivo) and Merck’s pembrolizumab (Keytruda) both hold extensive method-of-use patent portfolios covering specific tumor types, biomarker-selected patient populations (PD-L1 expression levels, MSI-H status), combination regimens with chemotherapy or other checkpoint inhibitors, and treatment-line specifications (first-line versus second-line use). These patents do not extend the core biologic patent life, but they do create litigation barriers for biosimilar entrants seeking to compete across the full approved indication set.<\/p>\n\n\n\n

For a biosimilar developer, a skinny label approach in oncology is commercially limiting. An oncology biosimilar that cannot legally promote use for the three most commercially important indications because of method-of-use patent coverage is launching with one hand tied. The commercial incentive to challenge those patents via IPR at the USPTO or via Paragraph IV for any ANDA-eligible components is high.<\/p>\n\n\n\n

When Does FDA Exclusivity Overlap With Method-of-Use Patent Protection?<\/strong><\/h3>\n\n\n\n

FDA exclusivity and method-of-use patent protection interact in ways that can compound the exclusivity runway. An NDA holder that studies an approved drug in a new population and obtains supplemental NDA approval can earn three-year clinical investigation exclusivity under the Hatch-Waxman Act for the new indication. If a method-of-use patent covering that indication also issues, the patent protection and the regulatory exclusivity layer together.<\/p>\n\n\n\n

Orphan drug exclusivity under 21 U.S.C. \u00a7 360bb provides seven years of exclusivity for drugs targeting rare diseases. When an originator obtains orphan designation for a new indication of an existing molecule and also holds method-of-use patents on that indication, the combined protection can extend well past the nominal compound expiry. Alexion Pharmaceuticals deployed this strategy for eculizumab (Soliris) across multiple rare complement-mediated disorders.<\/p>\n\n\n\n

\n\n\n\n

Polymorph Patents: Chemistry’s Most Contested Exclusivity Tool<\/strong><\/h2>\n\n\n\n

What Is a Drug Polymorph and Why Polymorphism Matters for Patents<\/strong><\/h3>\n\n\n\n

A polymorph is a distinct solid-state crystalline form of a chemical compound. The same molecule, the same atoms arranged in the same covalent structure, can pack into different three-dimensional lattice arrangements when crystallized. Each arrangement is a different polymorph, and different polymorphs have measurably different physical properties: melting point, solubility, dissolution rate, hygroscopicity, physical stability, and compressibility.<\/p>\n\n\n\n

For pharmaceuticals, these physical property differences can have clinical relevance. If Polymorph A dissolves at twice the rate of Polymorph B in simulated gastric fluid, and that dissolution difference translates to meaningfully faster or higher drug absorption, then Polymorph A and Polymorph B are not clinically equivalent. A formulation using Polymorph A could behave differently in patients than one using Polymorph B.<\/p>\n\n\n\n

Patent law does not require clinical differentiation for a polymorph patent to be valid. Under U.S. patent law, a polymorph patent is valid if the polymorph is novel and non-obvious. A newly discovered crystalline form of a known compound is novel if it has not previously been described in the literature or in prior patents. Whether it is non-obvious depends on whether a skilled formulation scientist would have had reason to look for additional crystal forms and a reasonable expectation of finding this specific one.<\/p>\n\n\n\n

AstraZeneca and Nexium: The Polymorph Evergreening Template<\/strong><\/h3>\n\n\n\n

AstraZeneca’s patent strategy around esomeprazole (Nexium) became the canonical example of polymorph and enantiomer-based exclusivity extension. The underlying compound, omeprazole (Prilosec), lost patent protection in the early 2000s. Before that happened, AstraZeneca had developed esomeprazole, the S-enantiomer of omeprazole, and obtained compound patent protection for the pure enantiomer.<\/p>\n\n\n\n

Beyond the enantiomer patent, AstraZeneca listed polymorph and formulation patents in the Orange Book for Nexium that covered specific crystalline forms of esomeprazole magnesium. When ANDA filers challenged those patents via Paragraph IV certifications in the early 2000s, the litigation generated 30-month stays and years of additional commercial exclusivity. Nexium became one of the best-selling drugs in history, generating revenues in excess of $6 billion annually at its peak, with much of that revenue protected by the secondary patent portfolio after the base omeprazole patents had expired.<\/p>\n\n\n\n

The commercial lesson from Nexium is that the polymorph patent is most powerful when combined with a regulatory switch (here, from Prilosec to Nexium via direct-to-consumer advertising) that shifts patient and prescriber preference to the newly protected product before the original product faces generic competition.<\/p>\n\n\n\n

How Courts Evaluate Polymorph Patent Obviousness Under KSR International<\/strong><\/h3>\n\n\n\n

The Supreme Court’s 2007 decision in KSR International Co. v. Teleflex Inc. elevated the obviousness standard for all patents, but its impact on polymorph patents has been particularly significant. KSR rejected rigid adherence to the ‘teaching-suggestion-motivation’ test for obviousness and emphasized that if a problem is known and the solution is within the skill of an ordinary practitioner, the result is likely obvious.<\/p>\n\n\n\n

Post-KSR, courts have asked whether routine screening for polymorphs, a standard practice in pharmaceutical development, means that any polymorph found through that screening is obvious. The Federal Circuit addressed this in a series of post-KSR decisions that resist a categorical answer. In Pfizer Inc. v. Apotex Inc. (2007), the court invalidated a salt form patent for amlodipine (Norvasc) on obviousness grounds, finding that screening for pharmaceutically acceptable salts was routine and that the besylate salt offered no unexpected properties. The decision shook confidence in the durability of salt form and polymorph patents for previously known compounds.<\/p>\n\n\n\n

Subsequent decisions have been more nuanced. When a polymorph patent discloses unexpected properties, such as anomalous physical stability or substantially improved bioavailability compared to what was predicted, courts are more receptive to non-obviousness arguments. Unexpected results are a secondary consideration in the obviousness analysis that can tip the outcome.<\/p>\n\n\n\n

Polymorph Patent Litigation Outcomes: Win Rates and Commercial Impact<\/strong><\/h3>\n\n\n\n

Empirical data on polymorph patent outcomes in Paragraph IV litigation shows lower survival rates than compound patents. A 2019 analysis of Hatch-Waxman litigation outcomes found that polymorph and salt form patents were invalidated at approximately twice the rate of compound patents in contested cases. The pattern reflects the basic legal reality: obviousness is easier to prove when the prior art includes the parent compound, the known practice of polymorph screening, and the standard techniques for characterizing crystal forms.<\/p>\n\n\n\n

Commercial impact, however, does not depend only on ultimate validity. A polymorph patent that is eventually invalidated at trial may still have delivered three or four years of 30-month stays and settlement-driven exclusivity before the adverse judgment. In a drug generating $2 billion per year, that process has enormous commercial value even if the patent does not survive.<\/p>\n\n\n\n

DrugPatentWatch data shows that many polymorph-patent challenges settle before a final judgment, often with authorized generic agreements or negotiated entry dates that preserve some exclusivity for the originator. The ‘nuisance value’ of polymorph patent litigation is substantial from both directions: originators pay to defend claims they may not fully believe in, and generic manufacturers pay to challenge them.<\/p>\n\n\n\n

Polymorph Patents and IPAB Proceedings: IPR as a Path Around Orange Book Stays<\/strong><\/h3>\n\n\n\n

Since the America Invents Act created inter partes review at the USPTO Patent Trial and Appeal Board (PTAB) in 2012, generic manufacturers have used IPR as a parallel invalidity challenge track that does not depend on triggering a Paragraph IV lawsuit. A generic company can file an IPR petition attacking a polymorph patent’s validity on prior art grounds while simultaneously proceeding with an ANDA that does not certify against that patent.<\/p>\n\n\n\n

The strategic appeal is significant. An IPR, if granted and decided in the petitioner’s favor, cancels the challenged claims without the need to survive litigation in district court. The Patent Trial and Appeal Board has been more willing than district courts to find polymorph claims obvious based on prior art showing routine screening practices, largely because the PTAB applies the broadest reasonable interpretation of claims and has judges with deeper chemistry expertise than the average district court judge.<\/p>\n\n\n\n

IPR win rates for pharmaceutical patents generally run higher than district court invalidity rates, though the PTAB’s pharmaceutical-specific jurisprudence has shifted somewhat following the Supreme Court’s 2018 decision in SAS Institute Inc. v. Iancu, which affected how partial institution decisions are handled.<\/p>\n\n\n\n

\n\n\n\n

Metabolite Patents: Protecting the Active Form of the Drug<\/strong><\/h2>\n\n\n\n

What Is a Drug Metabolite and When Is It Separately Patentable?<\/strong><\/h3>\n\n\n\n

A drug metabolite is a compound produced by the body’s metabolic processing of the administered drug. Many drugs are prodrugs: the administered compound has minimal pharmacological activity and is converted by enzymatic processes in the liver or other tissues into an active metabolite that produces the therapeutic effect. In other cases, the administered drug itself is active but generates active metabolites that contribute to or extend its pharmacological effect.<\/p>\n\n\n\n

A metabolite patent covers that downstream compound. If the active metabolite is a distinct chemical entity that has not previously been described, it is novel. Whether it is non-obvious depends on whether a person of skill in the art could have predicted its structure and activity from knowledge of the parent compound and metabolic chemistry.<\/p>\n\n\n\n

The Supreme Court’s 2006 decision in Metabolite Laboratories, Inc. v. Laboratory Corporation of America Holdings raised foundational questions about metabolite patent eligibility, though the Court ultimately dismissed the case without reaching the merits. In the pharmaceutical context, the critical question is whether claims to a metabolite found in the body after administration of a known drug constitute patent-eligible subject matter under 35 U.S.C. \u00a7 101 or represent a prohibited attempt to patent a natural phenomenon.<\/p>\n\n\n\n

The Natural Metabolite Problem: Mayo Collaborative Services v. Prometheus Laboratories<\/strong><\/h3>\n\n\n\n

The Supreme Court’s 2012 decision in Mayo Collaborative Services v. Prometheus Laboratories directly addressed whether a patent on the relationship between drug metabolite levels and treatment outcomes was valid. Prometheus held patents covering the correlation between thiopurine drug metabolite concentrations in a patient’s blood and the likelihood of efficacy or toxicity. The Court held that patents claiming laws of nature or natural correlations, even where those correlations were newly discovered, are not patent-eligible under \u00a7 101.<\/p>\n\n\n\n

Mayo’s impact on metabolite patent strategy is real but bounded. A patent claiming the natural metabolite compound itself, as a composition of matter with a specific structure and pharmaceutical utility, is generally treated differently from a patent claiming a correlation between metabolite levels and outcomes. The compound claim is more defensible under \u00a7 101 because it claims a specific molecule with defined structure, not a relationship between measured values and a therapeutic decision.<\/p>\n\n\n\n

Post-Mayo, pharmaceutical companies have structured metabolite patent claims carefully to focus on the compound’s structural identity and its demonstrated therapeutic uses, avoiding claim language that reads as a correlation between naturally occurring metabolite concentrations and patient outcomes. This drafting strategy reduces \u00a7 101 vulnerability while preserving the core commercial protection.<\/p>\n\n\n\n

Fexofenadine as Terfenadine’s Active Metabolite: How Seldane Became Allegra<\/strong><\/h3>\n\n\n\n

One of the clearest commercial examples of metabolite patent strategy is the relationship between terfenadine (Seldane) and fexofenadine (Allegra). Hoechst Marion Roussel (later acquired by Sanofi-Aventis) held compound patents on terfenadine, the first non-sedating antihistamine to achieve blockbuster status. When the FDA identified cardiac safety concerns related to terfenadine’s interaction with metabolic inhibitors, leading to QT prolongation, the regulatory pressure to withdraw the drug created a commercial crisis.<\/p>\n\n\n\n

The resolution was fexofenadine, the primary active metabolite of terfenadine. Hoechst had patented fexofenadine separately as a metabolite. When terfenadine was withdrawn from the U.S. market in 1998, Allegra (fexofenadine) was already FDA-approved and commercially established. The metabolite patent gave Hoechst\/Sanofi a new protected franchise from a compound that would otherwise have faced immediate generic competition.<\/p>\n\n\n\n

Fexofenadine’s metabolite patent protection eventually ran out, and the drug faced generic competition after 2005. But the metabolite strategy had purchased roughly seven years of branded sales for what was effectively the same therapeutic moiety as a compound with expired patent protection.<\/p>\n\n\n\n

Metabolite Patents in the Context of Prodrug Strategies: Lisdexamfetamine and Oseltamivir<\/strong><\/h3>\n\n\n\n

Prodrug strategies represent a variation on metabolite patent logic. A prodrug is designed from the outset to be metabolized to the active compound. The patent on the prodrug covers a distinct chemical entity from the active drug, so it does not depend on demonstrating that the metabolite is non-obvious in the abstract; the prodrug itself is the patented invention.<\/p>\n\n\n\n

Shire’s lisdexamfetamine (Vyvanse) is the commercial exemplar. Amphetamine salts (Adderall) had generic competition. Lisdexamfetamine is a prodrug of amphetamine, inactive until cleaved in the gut, patent-protected in its own right, and carrying an abuse-deterrence profile that was separately protected. Shire obtained Orange Book listings for the lisdexamfetamine compound patents that were wholly distinct from the amphetamine compound patents, creating a protected franchise from an active moiety that had been generic for decades.<\/p>\n\n\n\n

Roche’s oseltamivir (Tamiflu) follows comparable logic, though the prodrug relationship is less clinically central than the compound IP. The patent portfolio for oseltamivir included claims on the phosphate salt, the active carboxylate form, and specific synthesis routes, building a multi-layer protection that ran through the mid-2010s for most key markets.<\/p>\n\n\n\n

Metabolite Patent Filing Strategy: When and How to File for Maximum Coverage<\/strong><\/h3>\n\n\n\n

Optimal metabolite patent filing requires early metabolic profiling. Drug companies identify major metabolites during preclinical development and file patent applications on any metabolites that appear pharmacologically active or clinically relevant. The window for filing metabolite patents with the best novelty position is before academic publication of the parent compound’s metabolic profile, because once metabolite structures are disclosed in the scientific literature or in prior patents, the novelty case becomes complicated.<\/p>\n\n\n\n

The challenge is that early metabolic profiling may miss minor but important metabolites that only emerge in human clinical trials. Phase I trials generate detailed human pharmacokinetic data that may reveal unexpected active metabolites. Filing continuations or new applications on these late-identified metabolites is possible, but the novelty and non-obviousness case may be weaker if the parent compound and its basic metabolic pathways are already disclosed.<\/p>\n\n\n\n

Companies conducting drug development often use resources such as DrugPatentWatch to benchmark their metabolite patent filings against analogous competitive programs, checking whether structurally similar compounds in the prior art have already generated metabolite patents and how those were examined and litigated.<\/p>\n\n\n\n

\n\n\n\n

Patent Thickets: How the Four Secondary Patent Types Combine<\/strong><\/h2>\n\n\n\n

What Is a Patent Thicket in Pharmaceutical IP Strategy?<\/strong><\/h3>\n\n\n\n

A patent thicket is a dense cluster of overlapping patents covering multiple aspects of a single drug product. The term, borrowed from semiconductor industry discourse, describes a situation where multiple valid patents must each be cleared before a competitor can freely operate. In pharmaceuticals, a thicket typically combines the primary compound patent with formulation patents, method-of-use patents, polymorph patents, metabolite patents, process patents on synthesis routes, and device patents if the drug uses a delivery device.<\/p>\n\n\n\n

The commercial logic of a patent thicket is multiplication of legal risk for potential entrants. A generic manufacturer considering an ANDA filing against a thicket drug faces not one potential lawsuit but six or eight. Each lawsuit generates legal costs, potential 30-month stays, and liability risk. Even if the manufacturer believes all or most of the secondary patents are invalid or not infringed, the cost and delay of clearing every patent in the thicket can push entry dates years beyond any single patent’s expiry.<\/p>\n\n\n\n

AbbVie’s Humira Patent Thicket: A Case Study in Biologic IP Strategy<\/strong><\/h3>\n\n\n\n

AbbVie’s adalimumab (Humira) patent portfolio is the most-studied biologic patent thicket in the industry’s history. The core biologic patents, covering the fully human monoclonal antibody composition and its production methods, began expiring in the early 2020s. But AbbVie had accumulated over 130 patents related to Humira, covering formulations, manufacturing processes, antibody concentrations, indication-specific uses, device features of the auto-injector, and aspects of the antibody’s protein structure beyond the basic composition claims.<\/p>\n\n\n\n

Biosimilar developers including Amgen (Amjevita), AstraZeneca (Hadlima via Samsung Bioepis), and Pfizer (Abrilada) sought to launch adalimumab biosimilars as the core patents expired. AbbVie’s litigation strategy, backed by the breadth of the secondary patent portfolio, resulted in settlements with all major biosimilar developers that delayed U.S. launches until January 2023, years after the first core biologic patent expiration. In exchange for delayed entry, biosimilar developers typically received licenses, favorable pricing structures, and assurances of no further IP litigation.<\/p>\n\n\n\n

The commercial outcome for AbbVie was extraordinary. Humira generated approximately $21 billion in global revenues in 2022, its last full year of unchallenged U.S. market leadership. The secondary patent thicket had protected that revenue stream well beyond what the primary biologic IP would have supported alone.<\/p>\n\n\n\n

How Patent Thickets Affect Generic Entry Timelines and LOE Forecasting<\/strong><\/h3>\n\n\n\n

For analysts forecasting loss-of-exclusivity timelines, a patent thicket means that the ‘nominal’ LOE date, typically the primary compound patent expiry plus any \u00a7 156 extension, substantially understates the actual competitive entry risk. The relevant question is not when the compound patent expires, but when the last commercially significant secondary patent in the thicket expires or is invalidated.<\/p>\n\n\n\n

Tracking thicket depth requires patent-by-patent analysis. Each Orange Book-listed patent must be mapped to its legal basis, its expiry date, its challenge history, and an assessment of its likely validity under current doctrine. Services like DrugPatentWatch structure this data to allow analysts to identify which patents in a thicket have been challenged, which are subject to pending IPRs, and which remain unchallenged and therefore potentially enforceable through their full term.<\/p>\n\n\n\n

Industry analysts at firms like IQVIA and Evaluate Pharma have developed LOE models that weight thicket depth as a separate variable from compound patent expiry. A drug with a compound patent expiring in 2027 but six secondary patents running through 2031 carries a fundamentally different LOE risk profile than a drug where the compound patent is the only listed IP.<\/p>\n\n\n\n

Measuring Patent Thicket Density: Orange Book Listings as a Proxy<\/strong><\/h3>\n\n\n\n

The number of Orange Book-listed patents per NDA is a rough but useful proxy for thicket density. Drugs with more than five listed patents face measurably higher barriers to generic entry than drugs with one or two. Research published in journals including JAMA Internal Medicine has documented the correlation between Orange Book listing counts and delayed generic entry timelines, though causation is difficult to fully separate from product complexity and litigation resource availability.<\/p>\n\n\n\n

\n

‘Between 2005 and 2015, the median number of patents listed in the Orange Book per new molecular entity increased from 3.5 to 7.9, reflecting a systematic expansion of secondary patent filing strategies across the branded pharmaceutical industry.’ \u2014 Robin Feldman, University of California College of the Law San Francisco, cited in Mayo Clinic Proceedings<\/em> (2018) [1]<\/p>\n<\/blockquote>\n\n\n\n

The trend documented in that research has continued into the 2020s, with biologics showing even higher secondary IP densities than small molecules because of the additional layers available from manufacturing process patents, protein variant patents, and device patents on administration systems.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Exclusivity vs. Patent Exclusivity: How They Stack<\/strong><\/h2>\n\n\n\n

Five-Year NCE Exclusivity, Three-Year Clinical Exclusivity, and Orphan Drug Exclusivity in Combination With Secondary Patents<\/strong><\/h3>\n\n\n\n

FDA regulatory exclusivity and patent protection are parallel systems that can reinforce or partially overlap each other. For a new chemical entity (NCE), Hatch-Waxman provides five years of data exclusivity during which an ANDA cannot even be submitted, plus a one-year head start on any 30-month stay triggered by Paragraph IV challenges filed in the fourth or fifth year of that exclusivity period. For a drug approved for an additional indication or new clinical study, three-year clinical investigation exclusivity applies to the new use, blocking ANDA approval for that specific use for three years.<\/p>\n\n\n\n

Orphan drug exclusivity runs seven years from the date of first approval for the orphan indication and blocks approval of any ANDA or 505(b)(2) application for the same active moiety in the same indication. Secondary patents covering orphan indications stack their terms on top of the orphan exclusivity period, meaning that a method-of-use patent on an orphan indication expiring two years after the orphan exclusivity period provides a seamless transition from regulatory to patent exclusivity.<\/p>\n\n\n\n

Pediatric exclusivity adds six months to any FDA exclusivity period and six months to any listed patent’s exclusivity under the Hatch-Waxman framework. This extension is available for drugs that complete FDA-requested pediatric studies under the Best Pharmaceuticals for Children Act. For a drug with multiple listed patents, each of which benefits from six-month pediatric exclusivity extension, the aggregate effect on the LOE timeline can be substantial.<\/p>\n\n\n\n

How Secondary Patents Interact With 180-Day Generic Exclusivity<\/strong><\/h3>\n\n\n\n

The 180-day exclusivity period available to the first ANDA filer who submits a Paragraph IV certification is one of the most commercially valuable entitlements in generic drug regulation. For the first filer, it provides six months as the only generic competitor, a period during which combined branded and generic pricing dynamics allow revenues far above post-competitive equilibrium levels.<\/p>\n\n\n\n

Secondary patents interact with 180-day exclusivity in complex ways. If the first ANDA filer challenges the compound patent via Paragraph IV and wins, but the originator then lists additional secondary patents that are not challenged by that filer, the 180-day period may be forfeited or delayed if subsequent filers challenge the secondary patents first. The specific rules around forfeiture of 180-day exclusivity for failure to market within a defined period after patent resolution have been the subject of substantial FDA guidance and litigation, including the FTC’s challenges to certain exclusivity arrangements.<\/p>\n\n\n\n

\n\n\n\n

Secondary Patent Challenges: IPR, PGR, and District Court ANDA Litigation<\/strong><\/h2>\n\n\n\n

Inter Partes Review at the PTAB: Strategic Considerations for Generic Manufacturers<\/strong><\/h3>\n\n\n\n

Inter partes review allows any party to challenge a patent’s validity on prior art grounds within nine months of patent issuance (for post-grant review) or any time thereafter (for IPR). For secondary pharmaceutical patents, IPR provides several tactical advantages compared to district court ANDA litigation.<\/p>\n\n\n\n

First, IPR is faster. The PTAB operates on a 12-month statutory deadline from institution to final written decision, significantly shorter than district court patent trials, which typically run 24 to 36 months from complaint filing to verdict. A generic manufacturer that wins an IPR canceling secondary patent claims can potentially reach the market more quickly than through district court litigation alone.<\/p>\n\n\n\n

Second, IPR applies the preponderance of evidence standard for invalidity rather than the clear and convincing evidence standard in district court. This difference matters for secondary patents where prior art is strong but not conclusive. Claims that survive district court challenge on a clear and convincing burden may fall in IPR on a preponderance showing.<\/p>\n\n\n\n

Third, the PTAB panel, composed of administrative patent judges with technical and patent law expertise, is generally more comfortable with complex chemistry and pharmacology arguments than a generalist district court judge or jury. Polymorph obviousness arguments, in particular, tend to fare better before technically sophisticated PTAB panels.<\/p>\n\n\n\n

District Court ANDA Litigation: Delaware, New Jersey, and the Concentration of Pharmaceutical Patent Cases<\/strong><\/h3>\n\n\n\n

The vast majority of Paragraph IV ANDA litigation is filed in the District of Delaware or the District of New Jersey. Delaware draws pharmaceutical cases because many innovator pharmaceutical companies are incorporated there, establishing proper venue. New Jersey draws cases because it is the historical home of the U.S. pharmaceutical industry, with major research campuses for Johnson & Johnson, Merck, and Bristol-Myers Squibb in the state.<\/p>\n\n\n\n

Both courts have developed substantial expertise in pharmaceutical patent disputes, and their judges have handled the full range of secondary patent types. Chief Judge Colm Connolly in Delaware and the New Jersey district bench have issued decisions covering formulation, method-of-use, polymorph, and metabolite patents in the past decade that define the current doctrinal landscape.<\/p>\n\n\n\n

For secondary patent litigation, the choice of court affects not just legal strategy but tactical timing. Delaware courts have in recent years required parties to complete discovery more quickly, compressing pretrial timelines. New Jersey allows somewhat longer discovery periods for complex technical cases. These procedural differences affect when a generic manufacturer can expect a final judgment and whether it makes more sense to litigate through to verdict or negotiate a settlement with an authorized generic agreement.<\/p>\n\n\n\n

Reverse Payment Settlements and the Actavis Framework<\/strong><\/h3>\n\n\n\n

Settlement of secondary patent ANDA litigation frequently involves a payment from the innovator to the generic manufacturer in exchange for a delayed entry date. The Supreme Court’s 2013 decision in FTC v. Actavis established that such reverse payment settlements are subject to antitrust scrutiny under the rule of reason. A large and unjustified payment from innovator to generic that delays competition beyond what the patent’s expected litigation outcome would support can constitute an antitrust violation.<\/p>\n\n\n\n

Post-Actavis settlements have shifted from cash payments to non-cash value transfers that are harder to quantify: authorized generic licenses, co-promotion agreements, product supply arrangements, and access to the innovator’s compound library. The FTC has challenged several of these arrangements as effectively equivalent to cash payments under an Actavis analysis, with mixed success.<\/p>\n\n\n\n

For secondary patents specifically, the Actavis calculus differs from primary compound patent settlements because the expected litigation outcome for a polymorph or method-of-use patent is typically less favorable for the innovator than for a compound patent. A large payment to delay entry past a secondary patent’s likely invalidation date is more suspicious under the rule of reason than the same payment structured around a compound patent with strong validity prospects.<\/p>\n\n\n\n

\n\n\n\n

International Dimensions: How Secondary Patent Strategy Varies by Jurisdiction<\/strong><\/h2>\n\n\n\n

India’s Section 3(d) and Its Effect on Polymorph and Salt Form Patents<\/strong><\/h3>\n\n\n\n

India’s Patents Act, through Section 3(d), bars patents on new forms of known substances, including new polymorphs, salts, esters, and metabolites, unless the applicant demonstrates enhanced efficacy over the previously known form. This provision directly targets the secondary patent strategies that are routine in the United States and Europe.<\/p>\n\n\n\n

The Supreme Court of India’s 2013 decision in Novartis AG v. Union of India applied Section 3(d) to deny Novartis a patent on the beta-crystalline polymorph of imatinib mesylate, the active ingredient in Gleevec (Glivec). The court found that while the crystalline form had improved physical properties (flowability, thermodynamic stability), Novartis had not demonstrated enhanced therapeutic efficacy over the free base imatinib or the amorphous salt form. The decision kept imatinib off-patent in India, maintaining access for the generic industry there.<\/p>\n\n\n\n

Section 3(d) creates a bifurcated global IP landscape. A formulation or polymorph patent that is valid and enforceable in the United States and the EU may be unenforceable in India, meaning that generic manufacturers in India can produce products based on those secondary-protected forms and export to markets where the originator has no protection. This dynamic is particularly relevant for high-volume generics markets and for WHO procurement channels.<\/p>\n\n\n\n

European Patent Office Opposition Proceedings and Supplementary Protection Certificates<\/strong><\/h3>\n\n\n\n

In Europe, Supplementary Protection Certificates (SPCs) extend patent protection on authorized medicinal products beyond the base patent term, analogous to the U.S. \u00a7 156 patent term extension. SPCs can be obtained on the primary compound patent and, in some cases, on secondary patents covering the active ingredient as formulated in the authorized product.<\/p>\n\n\n\n

The European Patent Office’s opposition proceedings allow any third party to challenge a granted patent within nine months of grant. Generic manufacturers routinely file EPO oppositions against secondary pharmaceutical patents as a parallel challenge track to national litigation. A successful EPO opposition that revokes or limits a patent across all designated EPC countries provides much broader relief than a single-country invalidation.<\/p>\n\n\n\n

The Court of Justice of the European Union has issued several key decisions affecting SPC eligibility and scope that have important implications for secondary patent strategy. The 2018 Teva v. Gilead decision on SPC eligibility for combination products significantly restricted the ability to obtain SPCs for secondary compound combinations that were not independently claimed in the basic patent’s claims.<\/p>\n\n\n\n

\n\n\n\n

Commercial Intelligence: Identifying Secondary Patent Vulnerability in a Drug’s IP Portfolio<\/strong><\/h2>\n\n\n\n

How to Assess LOE Risk Using Orange Book Data and Patent Prosecution Histories<\/strong><\/h3>\n\n\n\n

A structured LOE risk assessment for a drug with secondary patent protection begins with pulling the complete Orange Book listing for the NDA. Each listed patent should be mapped by type (compound, formulation, method-of-use, polymorph, metabolite, process, device), by expiry date including any term adjustment and term extension, and by challenge history (Paragraph IV certifications received, litigation status, IPR petitions filed).<\/p>\n\n\n\n

DrugPatentWatch provides this structured view across the Orange Book, supplementing it with litigation histories, settlement records, and PTAB proceeding outcomes. For a drug with six Orange Book-listed secondary patents, the platform can identify which patents have been challenged, which have been defended successfully, and which remain unchallenged but may be vulnerable based on prior art analysis.<\/p>\n\n\n\n

Patent prosecution history review is the next layer of analysis. The file wrapper for each patent, available through the USPTO’s Patent Center, shows what prior art was cited during examination, what rejections were issued, and what arguments or claim amendments the applicant made to overcome those rejections. Claim amendments made to overcome prior art rejections narrow the claims through prosecution history estoppel and limit the doctrine of equivalents scope, potentially providing a design-around path for generic developers.<\/p>\n\n\n\n

Secondary Patent Financial Modeling: Revenue at Risk Calculation<\/strong><\/h3>\n\n\n\n

Revenue-at-risk calculation for secondary patents requires modeling two variables: the probability that each patent survives full-term (validity probability) and the probability that a generic product not infringing the patent can be developed and launched (design-around probability).<\/p>\n\n\n\n

For formulation patents with broad claims and strong prosecution histories, validity probability may be 60% to 70% in contested litigation and design-around probability may be relatively low for drugs where formulation changes affect bioequivalence. For polymorph patents covering forms without demonstrated enhanced efficacy, post-KSR validity probability may be below 40%, and design-around probability may be higher if multiple polymorphs can be formulated equivalently.<\/p>\n\n\n\n

Industry standard models discount the nominal patent expiry date by these probabilities to arrive at an expected generic entry date. A compound patent expiring in 2027, with a 70% validity probability and no viable design-around, extends the expected generic entry date to approximately 2025.6 in a probability-weighted model. A polymorph patent expiring in 2030 with 35% validity probability and a 50% design-around probability contributes far less extension to the expected entry date.<\/p>\n\n\n\n

What Investors and Analysts Miss When Modeling LOE for Branded Drugs<\/strong><\/h3>\n\n\n\n

The most common analytical error in LOE modeling is treating the primary compound patent expiry as synonymous with the LOE date. This error is compounded when secondary patents are dismissed as ‘soft IP’ without assessing their specific legal strength.<\/p>\n\n\n\n

A second common error is underestimating the commercial impact of 30-month stays triggered by secondary patent listings. Even if every listed secondary patent is ultimately invalidated, the cumulative delay from multiple sequential 30-month stays can push the commercial generic entry date two to four years past any individual patent’s expiry. The litigation process itself has option value for the innovator that is separate from the ultimate validity of the patents being defended.<\/p>\n\n\n\n

A third error is ignoring the settlement landscape. When evaluating LOE risk for a drug with multiple listed secondary patents and no pending Paragraph IV challenges, the absence of challenges does not mean the patents are strong. It may mean that no generic manufacturer has yet decided the drug is worth the litigation investment, or that the market is still growing and generic entry timing has not become commercially urgent.<\/p>\n\n\n\n

\n\n\n\n

When Secondary Patents Fail: Lessons From High-Profile Invalidations<\/strong><\/h2>\n\n\n\n

Pfizer’s Lyrica (Pregabalin) Method-of-Use Patent Invalidity in the UK<\/strong><\/h3>\n\n\n\n

Pfizer’s experience with pregabalin (Lyrica) in the UK illustrates the risks of relying on method-of-use patents for secondary exclusivity in a fragmented regulatory system. The compound patent on pregabalin expired in 2013. Pfizer held a method-of-use patent covering the treatment of pain, specifically peripheral and central neuropathic pain, which did not expire until 2017. Pfizer argued that generic manufacturers selling skinny-label pregabalin for epilepsy and anxiety, the non-patented indications, were inducing infringement when prescriptions for neuropathic pain were filled with generic product.<\/p>\n\n\n\n

The UK High Court and Court of Appeal delivered a series of conflicting decisions about whether prescribing and dispensing practices in the NHS constituted infringement of Pfizer’s method-of-use patent and what obligations the NHS had to prevent generic substitution for the patented indication. The litigation involved Pfizer, Warner-Lambert (its subsidiary), multiple generic manufacturers, and NHS England as a named party, and it became one of the most complex pharmaceutical patent disputes in UK legal history.<\/p>\n\n\n\n

The Supreme Court of the United Kingdom ultimately ruled in 2018 that Warner-Lambert’s claims failed on both infringement and validity grounds. The method-of-use patent for central neuropathic pain was held insufficient because the patent application’s data did not support the full breadth of the pain treatment claim as required under UK law’s plausibility standard.<\/p>\n\n\n\n

Clopidogrel Polymorph Patents and the Federal Circuit’s Obviousness Analysis<\/strong><\/h3>\n\n\n\n

Sanofi-Aventis held patents on clopidogrel bisulfate (Plavix), one of the best-selling drugs in history. The compound patent covered the R-enantiomer of clopidogrel, separated from the racemate that was in prior art. A polymorph patent covered specific crystalline forms of clopidogrel bisulfate.<\/p>\n\n\n\n

When Apotex filed an ANDA with a Paragraph IV certification against the clopidogrel patents, the ensuing litigation, Sanofi-Synthelabo v. Apotex, resulted in a critical test of both the enantiomer patent’s validity and the polymorph patent’s scope. The Federal Circuit ultimately upheld the key compound claims on the R-enantiomer, finding non-obviousness in the unexpected properties of the pure enantiomer versus the racemate. The polymorph issues in the case were partly superseded by the compound patent’s survival.<\/p>\n\n\n\n

The case established the importance of documented unexpected properties as evidence of non-obviousness in secondary patent prosecution and litigation. Innovators learned from the Plavix litigation that prospective documentation of polymorph and enantiomer properties during development, comparing them rigorously to the prior art forms, strengthens the secondary patent’s non-obviousness case substantially.<\/p>\n\n\n\n

Branded Drug Companies’ Strategic Response to Secondary Patent Invalidation<\/strong><\/h3>\n\n\n\n

When a secondary patent is invalidated, the commercial response typically involves one or more of four strategies. The first is an authorized generic launch, where the originator licenses a generic affiliate or third party to sell a generic version while the brand continues, capturing some of the market that would otherwise go entirely to the challenging manufacturer.<\/p>\n\n\n\n

The second is acceleration of a next-generation product. A reformulation with a genuinely superior profile, new delivery mechanism, or new indication can shift market share to a newly protected product before the generic of the old product captures prescriber habits. This was AstraZeneca’s strategy with Nexium following Prilosec’s generic challenge, though it required years of prior planning.<\/p>\n\n\n\n

The third strategy is price adjustment. Originators sometimes respond to generic entry for products with eroded secondary patent protection by reducing brand pricing to maintain formulary position and prescriber loyalty, accepting lower margins to preserve volume. This approach is uncommon for small molecules, where generic price erosion is typically too severe for branded price competition to be effective, but it appears in specialty and biologic markets.<\/p>\n\n\n\n

The fourth is litigation appeal and continuation. Originator companies routinely appeal adverse district court decisions, seeking reversal at the Federal Circuit and, in rare cases, seeking Supreme Court review. Secondary patent cases are appealed less frequently than compound patent cases because the commercial stakes are lower per patent, but appeals do occur when the district court ruling involves a legal question of broad applicability across a portfolio.<\/p>\n\n\n\n

\n\n\n\n

Patent Filing Best Practices: Building the Secondary Portfolio Early<\/strong><\/h2>\n\n\n\n

Optimal Timing for Formulation and Polymorph Patent Applications<\/strong><\/h3>\n\n\n\n

The timing of secondary patent filings is strategically critical. Filing too early creates problems with disclosure of prior art in subsequent patent prosecution and can result in narrow claims if the compound or formulation is not yet fully characterized. Filing too late risks having the primary compound’s publication or NDA disclosure become prior art against the secondary patent’s novelty or non-obviousness.<\/p>\n\n\n\n

Best practice for formulation patents is to begin filing as soon as the clinical formulation is substantially fixed, typically during Phase II trials. At that point, the excipient ratios, coating systems, and release kinetics are defined well enough to draft specific claims, and the filing date establishes priority against competitors’ research into similar formulation approaches.<\/p>\n\n\n\n

Polymorph patent filing requires systematic crystal form screening during formulation development, ideally beginning in early-stage development with comprehensive characterization of all identified forms. Forms with unexpected properties should be filed promptly. The prior art search should specifically identify any literature disclosures of crystal form screening for structurally similar compounds, because those disclosures are the most likely source of obviousness arguments in examination and litigation.<\/p>\n\n\n\n

Continuation Applications and Terminal Disclaimers in Secondary Patent Strategy<\/strong><\/h3>\n\n\n\n

Continuation applications allow patent applicants to file new claims on related inventions while maintaining the priority date of the original application. In secondary patent strategy, continuations serve multiple purposes. They extend the prosecution period, potentially leading to patent issuance dates that are later and therefore closer to anticipated ANDA filing periods. They allow the originator to adjust claim scope in response to competitive developments, narrowing or broadening claims as the prior art landscape evolves.<\/p>\n\n\n\n

Terminal disclaimers are required when a continuation patent would otherwise extend beyond the expiry of the parent patent and the claims are not patentably distinct. For secondary patents, terminal disclaimers can limit the extension benefit if the secondary patent’s claims are found too close to the compound patent’s claims. Careful claim differentiation during prosecution avoids terminal disclaimer requirements while maintaining the broadest possible independent claims.<\/p>\n\n\n\n

What Does Effective Secondary Patent Prosecution Look Like?<\/strong><\/h3>\n\n\n\n

Effective secondary patent prosecution documents unexpected properties rigorously. For a polymorph patent, the application should include comparative dissolution, stability, and physical characterization data showing how the claimed form differs from all known prior art forms. For a formulation patent, comparative bioavailability or pharmacokinetic data demonstrating non-obvious advantages of the specific formulation over prior art formulations strengthens the prosecution record.<\/p>\n\n\n\n

The claims should be drafted in independent and dependent layers, with the broadest reasonable claims at the independent level and progressively more specific claims at the dependent levels. If the broad independent claims are rejected during examination, the applicant can argue for the dependent claims and still obtain patent protection for the most commercially important aspects of the invention, even if the broadest claims are not allowed.<\/p>\n\n\n\n

Claims that recite functional language (such as ‘a formulation that releases at least 80% of the active ingredient within 2 hours’) are broader in scope than those reciting structural composition (such as ‘a formulation comprising 15% HPMC, 10% lactose, and 5% microcrystalline cellulose’). Functional claims are harder to design around but may face 35 U.S.C. \u00a7 112 written description challenges. Structural claims are more specific and easier to defend for enablement but are easier for generic developers to design around. Effective prosecution balances both approaches.<\/p>\n\n\n\n

\n\n\n\n

Future Landscape: AI Drug Discovery and the Secondary Patent Horizon<\/strong><\/h2>\n\n\n\n

Will AI-Discovered Drugs Change the Secondary Patent Playbook?<\/strong><\/h3>\n\n\n\n

AI-driven drug discovery platforms, including those deployed by companies like Recursion Pharmaceuticals, Exscientia (now part of Evotec), and Insilico Medicine, are compressing the timeline from target identification to clinical candidate. If the time from compound identification to clinical nomination decreases from six years to two or three, the compound patent filing date moves closer to the IND filing date, and the gap between compound patent term and commercial exclusivity shrinks somewhat.<\/p>\n\n\n\n

More significantly, AI platforms can systematically explore polymorph and salt form space before or during clinical development, identifying and characterizing all major solid-state forms of a candidate compound far earlier than was possible with traditional screening programs. This shifts polymorph patent filing earlier in the development timeline, reducing the risk that prior art publications on closely related structures create prior art problems. It also means that comprehensive polymorph screening becomes a standard early-stage activity rather than a late-stage formulation optimization task.<\/p>\n\n\n\n

For method-of-use patents, AI-driven target identification and indication expansion programs generate new indication hypotheses from existing drug data sets. These hypotheses, if validated in clinical trials, support fresh method-of-use patent filings for indications that were not contemplated at the time of the original compound patent filing. The AI discovery model may therefore extend the useful life of the method-of-use patent strategy by generating more indication expansion opportunities per compound.<\/p>\n\n\n\n

Biosimilar Patent Thickets: What Comes After the Humira Moment?<\/strong><\/h3>\n\n\n\n

The Humira biosimilar entry experience has set the template for how biologic patent thickets resolve in the U.S. market. The pattern is: extensive secondary patent portfolio, negotiated settlement agreements with delayed entry dates, simultaneous multi-biosimilar launch after the settlement window, rapid price erosion. The secondary patent thicket delays entry but does not prevent it indefinitely.<\/p>\n\n\n\n

The next generation of biologic patent thickets is already building around newer modalities. Antibody-drug conjugates (ADCs) have layered IP structures covering the antibody, the linker, the cytotoxic payload, the conjugation chemistry, and the manufacturing process. Gene therapies have IP covering the vector, the transgene, the production system, and the delivery method. RNA therapeutics have IP on the oligonucleotide sequence, the chemical modifications for stability, the lipid nanoparticle delivery system, and the targeting mechanism.<\/p>\n\n\n\n

Each of these layers represents a potential secondary patent category that can be deployed in combination to create a thicket comparable to Humira’s. For biosimilar and biogeneric developers entering these spaces, the secondary patent clearance challenge will be substantially more complex than it was for adalimumab.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n
    \n
  • Primary compound patents define nominal LOE dates, but formulation, method-of-use, polymorph, and metabolite patents determine when generic or biosimilar competition actually arrives at commercial scale.<\/li>\n\n\n\n
  • Formulation patents covering extended-release or complex delivery systems provide the most reliable secondary protection when claims are drafted with documented comparative data and the formulation genuinely improves patient utility.<\/li>\n\n\n\n
  • Method-of-use patents depend heavily on FDA indication coverage for Orange Book listing; skinny label strategies by generic manufacturers have become legally riskier since the GlaxoSmithKline v. Teva decision in 2021.<\/li>\n\n\n\n
  • Polymorph patents carry the highest invalidation risk of the four types, particularly post-KSR, but retain commercial value through litigation delay even when ultimate validity is uncertain.<\/li>\n\n\n\n
  • Metabolite patents offer durable protection when the metabolite is separately patentable as a composition of matter; the Mayo decision creates \u00a7 101 exposure for correlation-based metabolite claims but not for structural compound claims.<\/li>\n\n\n\n
  • The commercial power of any single secondary patent type is multiplied when patents are combined into a thicket, as demonstrated by Humira’s 130-patent portfolio and the resulting multi-year biosimilar entry delay.<\/li>\n\n\n\n
  • LOE analysis that stops at the compound patent expiry materially misstates generic entry risk for drugs with deep secondary patent portfolios; full Orange Book patent mapping and prosecution history review are required.<\/li>\n\n\n\n
  • International jurisdictions, particularly India via Section 3(d), provide substantially less secondary patent protection than the U.S. system, creating geographic segmentation in the LOE timeline that affects both commercial modeling and generics supply chain strategy.<\/li>\n\n\n\n
  • IPR at the PTAB offers generic manufacturers a faster, more expert, and procedurally lower-burden track for invalidating secondary patents compared to district court ANDA litigation.<\/li>\n\n\n\n
  • AI-driven drug discovery and polymorph screening are beginning to shift the secondary patent filing timeline earlier, potentially increasing both the breadth and earlier-acquired strength of secondary IP portfolios for next-generation drug programs.<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

    What is the difference between a primary compound patent and a secondary pharmaceutical patent?<\/strong><\/h3>\n\n\n\n

    A primary compound patent covers the active pharmaceutical ingredient’s molecular structure. A secondary patent covers other aspects of the drug product or its use, such as a specific crystalline form (polymorph), a controlled-release formulation, a method of treating a disease, or an active metabolite. Secondary patents are filed later in the development process and typically expire after the primary compound patent.<\/p>\n\n\n\n

    How many patents does a typical blockbuster drug have listed in the Orange Book?<\/strong><\/h3>\n\n\n\n

    The median number of Orange Book-listed patents per major branded drug has grown significantly over the past two decades. Research documents a range from 3 to 15 or more listed patents for high-revenue drugs, with biologics trending toward the higher end. The number correlates with the commercialization period of the drug: drugs that have been on the market longer accumulate more secondary patents as the originator files on formulation improvements, new indications, and other innovations post-launch.<\/p>\n\n\n\n

    Can a generic manufacturer ignore a method-of-use patent if they use a skinny label?<\/strong><\/h3>\n\n\n\n

    Not completely. A skinny label that carves out the patented indication reduces but does not eliminate infringement risk. After GlaxoSmithKline LLC v. Teva Pharmaceuticals USA (Federal Circuit, 2021), induced infringement claims can succeed even with a carve-out label if the manufacturer’s communications, including press releases, reference use of the drug for the patented indication. The degree of risk depends on the specific facts, including how dominant the patented indication is in total prescriptions for the drug.<\/p>\n\n\n\n

    What is the success rate for pharmaceutical patent challenges in IPR proceedings at the PTAB?<\/strong><\/h3>\n\n\n\n

    Institution rates for pharmaceutical IPR petitions have historically been around 60% to 70%, meaning that approximately 60% to 70% of pharmaceutical IPR petitions pass the threshold review and are instituted for full proceedings. Of instituted proceedings, claims are cancelled in whole or in part in a majority of cases, making IPR a significantly higher-risk forum for patent owners than district court litigation, where patent invalidation rates in fully litigated cases are lower.<\/p>\n\n\n\n

    How does India’s Section 3(d) affect the global strategy for polymorph patents?<\/strong><\/h3>\n\n\n\n

    Section 3(d) of the Indian Patents Act bars patents on new polymorphs, salts, and other new forms of known substances unless enhanced therapeutic efficacy is demonstrated. This means a polymorph patent valid in the U.S. and EU may be unenforceable in India, allowing Indian generic manufacturers to produce products based on those secondary-protected forms for Indian domestic consumption and for export to unprotected markets. Companies with India-targeted strategies must account for this gap in their global IP models.<\/p>\n\n\n\n

    What happens to exclusivity when a secondary patent is invalidated in ANDA litigation?<\/strong><\/h3>\n\n\n\n

    Invalidation of a secondary patent in final district court judgment removes that patent from the Orange Book listing and eliminates its exclusivity contribution. If additional secondary patents remain listed and unchallenged, the originator retains exclusivity for the remaining patents’ terms. If the invalidated patent was the last remaining IP barrier, commercial generic entry follows, subject to any remaining FDA exclusivity periods and the 180-day first-filer exclusivity for the winning challenger.<\/p>\n\n\n\n

    Can an originator obtain a patent term extension for a secondary patent?<\/strong><\/h3>\n\n\n\n

    Yes, under 35 U.S.C. \u00a7 156, patent term extension is available for the patent that claimed the ‘human drug product’ that was subject to the regulatory review period, limited to one extension per product. If the compound patent is extended, secondary patents covering the same product are generally not separately eligible for term extension. However, if the secondary patent claims a distinct aspect eligible under the statute and no term extension was taken on the compound patent, extension may be available. The rules are complex and product-specific.<\/p>\n\n\n\n

    How do authorized generics affect the commercial value of secondary patent exclusivity?<\/strong><\/h3>\n\n\n\n

    Authorized generics, where the originator licenses a generic affiliate or third-party manufacturer to sell a generic version, can erode the 180-day exclusivity of the first Paragraph IV filer. If an originator launches an authorized generic simultaneously with the first generic’s entry, it competes directly in the generic segment, reducing the first filer’s exclusivity premium. This strategy is particularly relevant when secondary patents are expiring or being invalidated, as it allows originators to participate in the generic market rather than ceding all volume.<\/p>\n\n\n\n

    What role does DrugPatentWatch play in secondary patent analysis?<\/strong><\/h3>\n\n\n\n

    DrugPatentWatch aggregates Orange Book patent listings, patent term extension records, Paragraph IV certification histories, PTAB IPR outcomes, and litigation case records into a structured database that allows analysts to map a drug’s full secondary patent landscape. It identifies which patents have been challenged, which have been successfully defended, which are subject to active proceedings, and when each is expected to expire, enabling both LOE risk modeling and competitive intelligence work.<\/p>\n\n\n\n

    Are there legislative proposals to limit secondary pharmaceutical patents in the United States?<\/strong><\/h3>\n\n\n\n

    Several legislative proposals have been introduced in Congress targeting secondary patent listings. The Affordable Prescriptions for Patients Act, proposed in various forms, would restrict the number of patents an originator can assert against a single ANDA or biosimilar applicant in litigation, targeting what the bill frames as anti-competitive use of patent thickets. The FTC Pharmaceutical Patent Review Act has proposed requiring FTC review of large Orange Book patent portfolios. None of these proposals has become law as of mid-2026, but the legislative interest reflects sustained policy concern about secondary patent strategies and their effect on drug pricing and generic competition timelines.<\/p>\n\n\n\n

    \n\n\n\n

    Citations<\/strong><\/h2>\n\n\n\n
      \n
    1. Feldman, R. (2018). May your drug price be evergreen. Journal of Law and the Biosciences<\/em>, 5(3), 590\u2013647. https:\/\/doi.org\/10.1093\/jlb\/lsy022<\/li>\n\n\n\n
    2. Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics<\/em>, 31(2), 327\u2013339. https:\/\/doi.org\/10.1016\/j.jhealeco.2012.01.004<\/li>\n\n\n\n
    3. Carrier, M. A. (2009). Innovation for the 21st century: Harnessing the power of intellectual property and antitrust law. Oxford University Press.<\/li>\n\n\n\n
    4. Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States. JAMA<\/em>, 316(8), 858\u2013871. https:\/\/doi.org\/10.1001\/jama.2016.11237<\/li>\n\n\n\n
    5. FTC v. Actavis, Inc., 570 U.S. 136 (2013).<\/li>\n\n\n\n
    6. KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).<\/li>\n\n\n\n
    7. GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021).<\/li>\n\n\n\n
    8. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).<\/li>\n\n\n\n
    9. Novartis AG v. Union of India, Civil Appeal No. 2706-2716 of 2013 (Supreme Court of India, 2013).<\/li>\n\n\n\n
    10. Pfizer Inc. v. Apotex Inc., 480 F.3d 1348 (Fed. Cir. 2007).<\/li>\n\n\n\n
    11. Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir. 2008).<\/li>\n\n\n\n
    12. Warner-Lambert Co LLC v Actavis Group PTC EHF [2018] UKSC 56.<\/li>\n\n\n\n
    13. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book), 44th edition. FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/<\/li>\n\n\n\n
    14. Grabowski, H., Long, G., & Mortimer, R. (2014). Recent trends in brand-name and generic drug competition. Journal of Medical Economics<\/em>, 17(3), 207\u2013214. https:\/\/doi.org\/10.3111\/13696998.2014.877456<\/li>\n\n\n\n
    15. Kesselheim, A. S., & Avorn, J. (2013). The role of litigation in defining drug risks. JAMA<\/em>, 309(8), 795\u2013796. https:\/\/doi.org\/10.1001\/jama.2013.607<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      The primary compound patent on a drug is the one the industry talks about. It sets the nominal expiry date […]<\/p>\n","protected":false},"author":1,"featured_media":38890,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38887"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38887\/revisions"}],"predecessor-version":[{"id":39289,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38887\/revisions\/39289"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38890"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}